The peptides specifically scheduled for review at the 2026 meeting include: BPC-157 free base BPC-157 acetate KPV (lysine-proline-valine tripeptide) TB-500 (thymosin beta-4 fragment) MOTS-c (mitochondrial-derived peptide) The committee will vote on whether each listed substance meets the statutory criteria under Section 503A(b)(1)(A)(i)(III) of the Federal Food, Drug, and Cosmetic Act for inclusion on the bulk drug substances list used in compounding
That convenience, plus a stable shelf life, is why capsule-form BPC-157 has become a popular choice for research use
Reconstituted solutions may have reduced stability and should be handled according to laboratory best practices
What is NNMT
in December 2024 the FDA's Pharmacy Compounding Advisory Committee voted against adding it to the final 503A bulks list, citing nonclinical toxicity, an unresolved cardiac signal, and immunogenicity risk
Over several weeks: Continued healing, progressive reduction in chronic symptoms, improved tissue function With ongoing treatment: Sustained benefits, better quality of life, restored function you thought you'd lost Everyone's healing timeline is different
